Johnson & Johnson
Close on Nov 3, 2026Market cap $641.44BP/E 40.4Yield 1.93%
Johnson & Johnson SPRAVATO (esketamine) by Year
SPRAVATO (esketamine) — Worldwide reported growth YoY (%) (%)
Johnson & Johnson SPRAVATO (esketamine): 57.4% in FY2025, up 1.0 pts from a year earlier.
Where the FY2025 figure comes from
“|| WW | 1,696 | 1,077 | 57.4 | 57.0 | 0.4”
Source: Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
Reported in Form 8-K EX-99.2 Segment Sales Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | SPRAVATO (esketamine) — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 57.4% | +1.0 pts | Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗ |
| FY2024 | Dec 29, 2024 | 56.4% | -27.7 pts | Form 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗ |
| FY2023 | Dec 31, 2023 | 84.1% | – | Form 8-K (a2023q4exhibit991.htm, filed 2024-01-23) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson SPRAVATO (esketamine) (%), annual FY2023–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-spravato-rep-yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.
See a number that looks wrong?